Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-07-14
2010-02-23
Saeed, Kamal A (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S238000
Reexamination Certificate
active
07666871
ABSTRACT:
The present invention discloses novel aryl oxazole compounds of Formula I (I), or pharmaceutically acceptable salts thereof, which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing and using such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using these compositions to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases. Formula I (I) or a pharmaceutically acceptable salt thereof, wherein: m is independenlly at each occurrence 1, 2, or 3, Z independently represents carbon (substituted with hydrogen or the optional substituents indicated herein) or nitrogen, provided that when Z is nitrogen then R6 is not attached to Z; R1 and R2 are independently —(C1—C7) alkyl (optionally substituted with one to three halogens), or R1 and R2 and the nitrogen to which they are attached form an azetidinyl ring, a pyrrolidinyl ring, or a piperidinyl ring, wherein further the azetidinyl, pyrrolidinyl, or piperidinyl ring so formed may be optionally substituted one to three times with R5; R6 is independently at each occurrence —H, -halogen, or —CH3.
REFERENCES:
patent: 3819037 (1979-01-01), None
patent: 03024694.6 (2009-10-01), None
patent: WO 95/09159 (1995-04-01), None
patent: WO 00/64884 (2000-11-01), None
patent: WO 02/076925 (2002-10-01), None
patent: WO 03/064411 (2003-08-01), None
patent: WO 2004-/054973 (2004-07-01), None
Golub et al. Science (1999), vol. 286 521-537.
Lala et al. Cancer and Metastasis Reviews (1998), 17(1), 91-106.
Gripenberg, M, Scand. J. Rheumatology, vol. 10 (2) 1981, 85-91.
“Epilepsy.” Retrieved online [May 28, 2008] via Internet, URL: http://www.nlm.nih.gov/medlineplus/epilepsy.html.
“Parkinson's Disease.” Retrieved online [May 28, 2008] via Internet, URL: http://www.nlm.nih.gov/medlineplus/parkinsonsdisease.html.
“Anxiety.” Retrieved online [May 28, 2008] via Internet, URL: http://www.nlm.nih.gov/medlineplus/anxiety.html#cat3.
“Dementia.” Retrieved online [May 28, 2008] via Internet, URL: http://www.nlm.nih.gov/medlineplus/dementia.html#cat5.
“Autism.” Retrieved online [May 28, 2008] via Internet, URL: http://www.nlm.nih.gov/medlineplus/autism.html.
“Attention deficit hyperactivity disorder.” Retrieved online [May 28, 2008] via Internet, URL: http://www.nlm.nih.gov/medlineplus/attentiondeficithyperactivitydisorder.html#cat3.
“Cancer.” Retrieved online [May 28, 2008] via Internet, URL: http://www.nlm.nih.gov/medlineplus/cancer.html.
Blum E. et al., “Design and Synthesis of Novel Ligands for the 5-HT3 and the 5-HT4 Receptor”Bioorganic&Medicinal Chemistry Letters, vol. 2, No. 5, pp. 461-466, 1992.
Beavers Lisa Selsam
Boulet Serge Louis
Finn Terry Patrick
Gadski Robert Alan
Hornback William Joseph
Eli Lilly and Company
Saeed Kamal A
Shterengarts Samantha L
Wood Dan L.
LandOfFree
Oxazole derivatives as histamine H3 receptor agents,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oxazole derivatives as histamine H3 receptor agents,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oxazole derivatives as histamine H3 receptor agents,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4170292